Melanoma was slower to recur in patients receiving Merck and Moderna's mRNA vaccine with Keytruda, supporting use of the ...
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rocketing higher Wednesday morning, with the stock up 93% to $121 ...
The latest results give investors confidence in the drug's ability to be approved in another indication for which there are ...
PleoPharma, Inc., a clinical-stage development company focused on cannabis-related health issues, today announced the award of a $6.5 million, three-year grant from the National Institute on Drug ...
Today, Aug. 19, 2026, Moderna's personalized cancer vaccine met its late-stage goal, with the company and Merck planning an ...
EyePoint, Inc. is rated a Sell, citing unfavorable risk/reward and concerns about commercial relevance against ...
Your resource for the hottest moving stocks and news. We cover all sectors and markets giving everyday investors access to ...
Total revenue increases by 14% to CHF 119 million Operating profit increases by 32% to CHF 32 million and net profit by 77% to CHF 28 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results